Related Experiment Video
Updated: Jun 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Co-lethality studied as an asset against viral drug escape: the HIV protease case
Sophie Brouillet1, Thomas Valere, Emmanuelle Ollivier
1Atelier de Bio Informatique, F-75005, Paris, France.
Background:
Co-lethality, or synthetic lethality is the documented genetic situation where two, separately non-lethal mutations, become lethal when combined in one genome. Each mutation is called a "synthetic lethal" (SL) or a co-lethal. Like invariant positions, SL sets (SL linked couples) are choice targets for drug design against fast-escaping RNA viruses: mutational viral escape by loss of affinity to the drug may induce (synthetic) lethality.
Results:
From an amino acid sequence alignment of the HIV protease, we detected the potential SL couples, potential SL sets, and invariant positions. From the 3D structure of the same protein we focused on the ones that were close to each other and accessible on the protein surface, to possibly bind putative drugs. We aligned 24,155 HIV protease amino acid sequences and identified 290 potential SL couples and 25 invariant positions. After applying the distance and accessibility filter, three candidate drug design targets of respectively 7 (under the flap), 4 (in the cantilever) and 5 (in the fulcrum) amino acid positions were found.
Conclusions:
These three replication-critical targets, located outside of the active site, are key to our anti-escape strategy. Indeed, biological evidence shows that 2/3 of those target positions perform essential biological functions. Their mutational variations to escape antiviral medication could be lethal, thus limiting the apparition of drug-resistant strains.
Reviewers:
This article was reviewed by Arcady Mushegian, Shamil Sunyaev and Claus Wilke.
Insights
Synthetic lethality (SL) identifies pairs of mutations that are lethal together, offering new drug targets for RNA viruses. This study found three potential drug targets in HIV protease that could limit drug resistance.
Area of Science:
- Virology
- Computational Biology
- Drug Discovery
Background:
- Synthetic lethality (SL) describes conditions where two non-lethal mutations become lethal when combined.
- SL sets are promising targets for antiviral drug design, particularly against RNA viruses prone to mutational escape.
- Viral escape mutations can induce synthetic lethality, presenting a strategy to combat drug resistance.
Purpose of the Study:
- To identify potential synthetic lethal (SL) couples and invariant positions in HIV protease.
- To pinpoint accessible surface regions on the HIV protease for drug binding.
- To discover novel drug targets for antiviral therapies that minimize resistance.
Main Methods:
- Amino acid sequence alignment of 24,155 HIV protease sequences.
- Analysis of 3D protein structures to identify surface-accessible regions.
- Application of distance and accessibility filters to pinpoint potential drug targets.
Main Results:
- Identified 290 potential SL couples and 25 invariant positions in HIV protease.
- Discovered three candidate drug design targets comprising 7, 4, and 5 amino acid positions.
- Located these targets outside the active site, in regions critical for replication.
Conclusions:
- The identified targets are crucial for viral replication and located outside the active site.
- Mutations at these target sites could induce lethality, thus limiting antiviral drug resistance.
- These findings offer a novel anti-escape strategy for developing effective antiviral medications.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Subviral Agents
Inhibitors Of Virion Release
Retroviruses